REVIEW article
Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1643068
A Case Displaying the Importance of JAK1 And JAK2 Gene Transcription in Antifungal Defense Against Coccidioidomycosis
Provisionally accepted
- 1Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, United States
- 2The University of Arizona College of Medicine Phoenix, Phoenix, United States
- 3Grenada, Saint George's, Grenada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This case report explores the consequences of ruxolitinib via inhibition janus kinase 1 (JAK1) and JAK2 pathways in the context of fungal defense in a patient diagnosed with pulmonary coccidioidomycosis during ruxolitinib therapy for polycythemia vera. The patient experienced a relapse of pulmonary coccidioidomycosis after antifungal treatment was discontinued while continuing ruxolitinib use. This case illustrates the heightened risk of discontinuing antifungal therapy in endemic regions, emphasizing the critical need for continued monitoring. Furthermore, this case underscores the vital role of the JAK1 and JAK2 signaling cascade, particularly the interferon-gamma (INF-γ)-JAK1 and JAK2-signal transducer and activator of transcription 1 (STAT) axis, in antifungal defense. Recent studies have revealed that the loss of function in JAK1 (but not JAK2), leads to impaired macrophage activation and reduced T-helper 1 (Th1) cell responses, thereby compromising the body's ability to fight off dimorphic fungi, such as Coccidioides. Other proposed fungal immune mechanisms in the JAK-STAT pathway are discussed. Clinicians tailoring JAK inhibitor treatment options for patients must be aware of the INF-γ-JAK1-STAT pathway's pivotal role in antifungal defense.
Keywords: JAK1 and JAK2 inhibitors, Ruxolitinb, Coccidioidomycosis, Coccidioidomycosis/immunology, JAK STAT signaling pathway, antifungal immunity
Received: 12 Jun 2025; Accepted: 05 Sep 2025.
Copyright: © 2025 Priessnitz, Colore and Nicolasora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jennifer K Priessnitz, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, United States
Nelson Nicolasora, The University of Arizona College of Medicine Phoenix, Phoenix, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.